SYMLIN
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2017 | $181,279 | 37 | 33 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $177,154 | 4 | 97.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4,125 | 33 | 2.3% |
Payments by Type
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Randomized, Single Blind, Two Way Crossover, Placebo Controlled Phase I Study to Compare the 24 hour Glucose Profile and Safety of Pramlintide and Insulin, Co Administered in a Fixed Dose Ratio, Versus Placebo and Insulin in Patients With Type 1 Diabetes Mellitus With Inadequate Glycemic Control | AstraZeneca UK Limited | $177,154 | 0 |
Top Doctors Receiving Payments for SYMLIN
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Chattanooga, TN | $177,154 | 4 |
| , M.D | Endocrinology, Diabetes & Metabolism | Miami, FL | $125.00 | 1 |
| , MD | Internal Medicine | Allentown, PA | $125.00 | 1 |
| , MD | Endocrinology, Diabetes & Metabolism | Monrovia, CA | $125.00 | 1 |
| , D.O | Family Medicine | Pryor, OK | $125.00 | 1 |
| , DO | Internal Medicine | Harrisburg, PA | $125.00 | 1 |
| , M.D | Family Medicine | Tulsa, OK | $125.00 | 1 |
| , M.D | Specialist | Encino, CA | $125.00 | 1 |
| , D.O | Internal Medicine | Lamar, MO | $125.00 | 1 |
| , MD | Internal Medicine | Overland Park, KS | $125.00 | 1 |
| , M.D | Endocrinology, Diabetes & Metabolism | Rockville, MD | $125.00 | 1 |
| , MD | Internal Medicine | Dayton, OH | $125.00 | 1 |
| , M.D | Internal Medicine | Rochester Hills, MI | $125.00 | 1 |
| , MD | Endocrinology, Diabetes & Metabolism | Miami, FL | $125.00 | 1 |
| , M.D | Endocrinology, Diabetes & Metabolism | Encino, CA | $125.00 | 1 |
| , DO | Internal Medicine | Saint Louis, MO | $125.00 | 1 |
| , MD | Endocrinology, Diabetes & Metabolism | Great Neck, NY | $125.00 | 1 |
| , M.D | Family Medicine | Prairieville, LA | $125.00 | 1 |
| , MD | Endocrinology, Diabetes & Metabolism | Castro Valley, CA | $125.00 | 1 |
| , M.D | Internal Medicine | Mobile, AL | $125.00 | 1 |
| , M.D | Endocrinology, Diabetes & Metabolism | Louisville, KY | $125.00 | 1 |
| , MD FACP CDE | Internal Medicine | Cleveland, OH | $125.00 | 1 |
| , MD FACP FACN FACE | Endocrinology, Diabetes & Metabolism | Peoria, IL | $125.00 | 1 |
| , MD | Endocrinology, Diabetes & Metabolism | Fort Wayne, IN | $125.00 | 1 |
| , D.O., M.S | Endocrinology, Diabetes & Metabolism | Southfield, MI | $125.00 | 1 |
Manufacturing Companies
- AstraZeneca UK Limited $177,154
- AstraZeneca Pharmaceuticals LP $4,125
Product Information
- Type Drug
- Total Payments $181,279
- Total Doctors 33
- Transactions 37
About SYMLIN
SYMLIN is a drug associated with $181,279 in payments to 33 healthcare providers, recorded across 37 transactions in the CMS Open Payments database. The primary manufacturer is AstraZeneca UK Limited.
Payment data is available from 2017 to 2017. In 2017, $181,279 was paid across 37 transactions to 33 doctors.
The most common payment nature for SYMLIN is "Unspecified" ($177,154, 97.7% of total).
SYMLIN is associated with 1 research study, including "A Randomized, Single Blind, Two Way Crossover, Placebo Controlled Phase I Study to Compare the 24 hour Glucose Profile and Safety of Pramlintide and Insulin, Co Administered in a Fixed Dose Ratio, Versus Placebo and Insulin in Patients With Type 1 Diabetes Mellitus With Inadequate Glycemic Control" ($177,154).